Delayed gastric emptying in Parkinson's disease

Movement Disorders

Volumn 29, Issue 1, 2014, Pages 23-32

  Marrinan, Sarah ^a   Emmanuel, Anton V ^b   Burn, David J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Gastrointestinal hormones; Gastrointestinal motility; Gastroparesis; Ghrelin; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CHOLECYSTOKININ; DOPAMINE RECEPTOR STIMULATING AGENT; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LEVODOPA; MACROLIDE; METOCLOPRAMIDE; MOTILIN; PEPTIDE YY;

BRAIN DEPTH STIMULATION; CENTRAL NERVOUS SYSTEM; DELAYED STOMACH EMPTYING; DIFFUSE LEWY BODY DISEASE; DRUG ABSORPTION; GASTROINTESTINAL SYMPTOM; HELICOBACTER PYLORI; HORMONAL REGULATION; HUMAN; NERVE PLEXUS; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STOMACH DISEASE; STOMACH EMPTYING; STOMACH FUNCTION; STOMACH MOTILITY; STOMACH PARESIS; STOMACH PRESSURE; SUBTHALAMIC NUCLEUS; SYSTEMATIC REVIEW; VAGUS NERVE DISEASE; WEIGHT GAIN;

GASTROINTESTINAL HORMONES; GASTROINTESTINAL MOTILITY; GASTROPARESIS; GHRELIN; PARKINSON'S DISEASE;

ENTERIC NERVOUS SYSTEM; GASTRIC EMPTYING; GASTROPARESIS; HUMANS; PARKINSON DISEASE;

EID: 84892949302     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25708     Document Type: Review

References (120)

1. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003;2:107-116.
2. Martinez-Martin P. The importance of non-motor disturbances to quality of life in Parkinson's disease. J Neurol Sci 2011;310:12-16.
3. Rodriguez-Violante M, Cervantes-Arriaga A, Villar-Velarde A, Corona T. Prevalence of non-motor dysfunction among Parkinson's disease patients from a tertiary referral center in Mexico City. Clin Neurol Neurosurg 2010;112:883-885.
4. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2011;17:10-15.
5. Cloud LJ, Greene JG. Gastrointestinal features of Parkinson's disease. Curr Neurol Neurosci Rep 2011;11:379-384.
6. Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991;6:151-156.
7. Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 2001;92:76-85.
8. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456-462.
9. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007;22:1581-1586.
10. Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009;73:1752-1758.
11. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72.
12. Cersosimo MG, Benarroch EE. Autonomic involvement in Parkinson's disease: Pathology, pathophysiology, clinical features and possible peripheral biomarkers. J Neurol Sci 2012;313:57-63.
13. Sanger GJ, Lee K. Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders. Nat Rev Drug Discov 2008;7:241-254.
14. Ejskjaer N, Vestergaard ET, Hellstrom PM, et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009;29:1179-1187.
15. Shin A, Camilleri M, Busciglio I, et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 2013;36:41-48.
16. Andrews ZB. The extra-hypothalamic actions of ghrelin on neuronal function. Trends Neurosci 2011;34:31-40.
17. Bayliss JA, Andrews ZB. Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of metabolic neuroprotection. Ther Adv Endocrinol Metab 2013;4:25-36.
18. Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW. Textbook of Gastroenterology. Oxford, UK: Blackwell Publishing Ltd.; 2009.
19. Cannon WB, Lieb CW. The receptive relaxation of the stomach. Am J Physiol 1911;29:267-273.
20. Kindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 2006;55:1685-1691.
21. Hellstrom PM, Gryback P, Jacobsson H. The physiology of gastric emptying. Best Pract Res Clin Anaesthesiol 2006;20:397-407.
22. Khoo J, Rayner CK, Feinle-Bisset C, Jones KL, Horowitz M. Gastrointestinal hormonal dysfunction in gastroparesis and functional dyspepsia. Neurogastroenterol Motil 2010;22:1270-1278.
23. Vincent RP, Ashrafian H, le Roux CW. Mechanisms of disease: the role of gastrointestinal hormones in appetite and obesity. Nat Clin Pract Gastroenterol Hepatol 2008;5:268-277.
24. Langley JN. The autonomic nervous system. Brain 1903;26:1-26.
25. Derkinderen P, Rouaud T, Lebouvier T, Bruley des Varannes S, Neunlist M, De Giorgio R. Parkinson disease: the enteric nervous system spills its guts. Neurology 2011;77:1761-1767.
26. MacGregor IL, Martin P, Meyer JH. Gastric emptying of solid food in normal man and after subtotal gastrectomy and truncal vagotomy with pyloroplasty. Gastroenterology 1977;72:206-211.
27. Fujii C, Harada S, Ohkoshi N, et al. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clin Genet 1999;56:394-399.
28. Goldman JG, Goetz CG, Berry-Kravis E, Leurgans S, Zhou L. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol 2004;61:1280-1284.
29. Smolnik R, Fischer S, Hagenah J, Kis B, Born J, Vieregge P. Brain potential signs of slowed stimulus processing following cholecystokinin in Parkinson's disease. Psychopharmacology (Berl) 2002;161:70-76.
30. Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A 2009;106:1285-1290.
31. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002;302:881-888.
32. Perry T, Lahiri DK, Chen D, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002;300:958-966.
33. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 2013;123:2730-2736.
34. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134.
35. Tanaka Y, Kato T, Nishida H, et al. Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the 13C-acetate breath test. J Neurol 2011;258:421-426.
36. Unger MM, Moeller JC, Mankel K, et al. Patients with idiopathic rapid-eye-movement sleep behavior disorder show normal gastric motility assessed by the 13C-octanoate breath test. Mov Disord 2011;26:2559-2563.
37. Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion-cell loss in achalasia-similarity to Parkinsons disease. Gastroenterology 1984;87:848-856.
38. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathologica 2010;119:689-702.
39. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997;38:2-7.
40. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: the dual hit theory revisited. Ann N Y Acad Sci 2009;1170:615-622.
41. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord 2010;16:79-84.
42. Angot E, Steiner JA, Lema Tome CM, et al. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One 2012;7:e39465.
43. Braak H, Del Tredici K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 2004;25:19-23.
44. Danzer KM, Haasen D, Karow AR, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007;27:9220-9232.
45. Danzer KM, Krebs SK, Wolff M, Birk G, Hengerer B. Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J Neurochem 2009;111:192-203.
46. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009;106:13010-13015.
47. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A 2009;106:12571-12572.
48. Drolet RE, Cannon JR, Montero L, Greenamyre JT. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis 2009;36:96-102.
49. Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 2010;5:e8762.
50. Pan-Montojo F, Schwarz M, Winkler C, et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2012;2:898.
51. Tasselli M, Chaumette T, Paillusson S, et al. Effects of oral administration of rotenone on gastrointestinal functions in mice. Neurogastroenterol Motil 2013;25:e183-e193.
52. Parkman HP, Hasler WL, Fisher RS; American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004;127:1592-1622.
53. Dudekula A, O'Connell M, Bielefeldt K. Hospitalizations and testing in gastroparesis. J Gastroenterol Hepatol 2011;26:1275-1282.
54. Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Digest Dis Sci 1998;43:2398-2404.
55. Jung H-K, Choung RS, Locke GR, III, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 2009;136:1225-1233.
56. Heetun ZS, Quigley EM. Gastroparesis and Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2012;18:433-440.
57. Cersosimo MG, Raina GB, Pecci C, et al. Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. J Neurol 2013;260:1332-1338.
58. Suzuki A, Asahina M, Ishikawa C, et al. Impaired circadian rhythm of gastric myoelectrical activity in patients with multiple system atrophy. Clin Auton Res 2005;15:368-372.
59. Tanaka Y, Kato T, Nishida H, et al. Is there delayed gastric emptying in patients with multiple system atrophy? An analysis using the 13C-acetate breath test. J Neurol 2012;259:1448-1452.
60. Berkowitz DM, McCallum RW. Interaction of levodopa and metoclopramide on gastric emptying. Clin Pharmacol Ther 1980;27:414-420.
61. Robertson DR, Renwick AG, Macklin B, et al. The influence of levodopa on gastric emptying in healthy elderly volunteers. Eur J Clin Pharmacol 1992;42:409-412.
62. Robertson DRC, Renwick AG, Wood ND, et al. The influence of levodopa on gastric-emptying in man. Br J Clin Pharmacol 1990;29:47-53.
63. Waller DG, Roseveare C, Renwick AG, Macklin B, George CF. Gastric emptying in healthy volunteers after multiple doses of levodopa. Br J Clin Pharmacol 1991;32:691-695.
64. Arai E, Arai M, Uchiyama T, et al. Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease. Brain 2012;135:1478-1485.
65. Holmberg B, Corneliusson O, Elam M. Bilateral stimulation of nucleus subthalamicus in advanced Parkinson's disease: no effects on, and of, autonomic dysfunction. Mov Disord 2005;20:976-981.
66. Hwynn N, Ul Haq I, Malaty IA, et al. Effect of deep brain stimulation on Parkinson's nonmotor symptoms following unilateral DBS: a pilot study. Parkinsons Dis 2011;2011:507416.
67. Witjas T, Kaphan E, Régis J, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord 2007;22:1729-1734.
68. Zibetti M, Torre E, Cinquepalmi A, et al. Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. Eur Neurol 2007;58:218-223.
69. Canteras NS, Shammah-Lagnado SJ, Silva BA, Ricardo JA. Afferent connections of the subthalamic nucleus: a combined retrograde and anterograde horseradish peroxidase study in the rat. Brain Res 1990;513:43-59.
70. Klein J, Soto-Montenegro ML, Pascau J, et al. A novel approach to investigate neuronal network activity patterns affected by deep brain stimulation in rats. J Psychiatr Res 2011;45:927-930.
71. Limousin P, Greene J, Pollak P, Rothwell J, Benabid AL, Frackowiak R. Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease. Ann Neurol 1997;42:283-291.
72. Schulte T, Brecht S, Herdegen T, Illert M, Mehdorn HM, Hamel W. Induction of immediate early gene expression by high-frequency stimulation of the subthalamic nucleus in rats. Neuroscience 2006;138:1377-1385.
73. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996;46:1051-1054.
74. Goetze O, Nikodem AB, Wiezcorek J, et al. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil 2006;18:369-375.
75. Goetze O, Wieczorek J, Mueller T, Przuntek H, Schmidt WE, Woitalla D. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Neurosci Lett 2005;375:170-173.
76. Hardoff R, Sula M, Tamir A, et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 2001;16:1041-1047.
77. Thomaides T, Karapanayiotides T, Zoukos Y, et al. Gastric emptying after semi-solid food in multiple system atrophy and Parkinson disease. J Neurol 2005;252:1055-1059.
78. Nyholm D, Lennernas H. Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opin Drug Metab Toxicol 2008;4:193-203.
79. Doi H, Sakakibara R, Sato M, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. J Neurol Sci 2012;319:86-88.
80. Muller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 2006;29:61-67.
81. Djaldetti R, Koren M, Ziv I, Achiron A, Melamed E. Effect of cisapride on response fluctuations in Parkinson's disease. Mov Disord 1995;10:81-84.
82. Neira WD, Sanchez V, Mena MA, Deyebenes JG. The effects of cisapride on plasma l-dopa levels and clinical-response in Parkinson's disease. Mov Disord 1995;10:66-70.
83. Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee P-L. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord 2008;23:1696-1700.
84. Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 2006;66:1824-1829.
85. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-660.
86. Williams DL, Grill HJ, Cummings DE, Kaplan JM. Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology 2003;144:5184-5187.
87. Unger MM, Moeller JC, Mankel K, et al. Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease? J Neurol 2011;258:982-990.
88. Ejskjaer N, Wo JM, Esfandyari T, et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25:e140-e150.
89. Murray CD, Martin NM, Patterson M, et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005;54:1693-1698.
90. Wang L, Murphy NP, Stengel A, et al. Ghrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats. Neurogastroenterol Motil 2012;24:e235-e245.
91. Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson's disease. Eur J Clin Nutr 1992;46:879-884.
92. Walker R, Davidson M, Gray W. Gender differences in 1-year survival rates after weight loss in people with idiopathic Parkinson's disease. Int J Palliat Nurs 2012;18:35-39.
93. Fiszer U, Michalowska M, Baranowska B, et al. Leptin and ghrelin concentrations and weight loss in Parkinson's disease. Acta Neurol Scand 2010;121:230-236.
94. Bannier S, Montaurier C, Derost PP, et al. Overweight after deep brain stimulation of the subthalamic nucleus in Parkinson disease: long term follow-up. J Neurol Neurosurg Psychiatry 2009;80:484-488.
95. Barichella M, Marczewska AM, Mariani C, Landi A, Vairo A, Pezzoli G. Body weight gain rate in patients with Parkinson's disease and deep brain stimulation. Mov Disord 2003;18:1337-1340.
96. Macia F, Perlemoine C, Coman I, et al. Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight. Mov Disord 2004;19:206-212.
97. Montaurier C, Morio B, Bannier S, et al. Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation. Brain 2007;130(Pt 7):1808-1818.
98. Novakova L, Ruzicka E, Jech R, Serranova T, Dusek P, Urgosik D. Increase in body weight is a non-motor side effect of deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neuroendocrinol Lett 2007;28:21-25.
99. Strowd RE, Cartwright MS, Passmore LV, Ellis TL, Tatter SB, Siddiqui MS. Weight change following deep brain stimulation for movement disorders. J Neurol 2010;257:1293-1297.
100. Tuite PJ, Maxwell RE, Ikramuddin S, et al. Weight and body mass index in Parkinson's disease patients after deep brain stimulation surgery. Parkinsonism Relat Disord 2005;11:247-252.
101. Visser-Vandewalle V, van der Linden C, Temel Y, et al. Long-term effects of bilateral subthalamic nucleus stimulation in advanced Parkinson disease: a four year follow-up study. Parkinsonism Relat Disord 2005;11:157-165.
102. Corcuff JB, Krim E, Tison F, et al. Subthalamic nucleus stimulation in patients with Parkinson's disease does not increase serum ghrelin levels. Br J Nutr 2006;95:1028-1029.
103. Novakova L, Haluzik M, Jech R, Urgosik D, Ruzicka F, Ruzicka E. Hormonal regulators of food intake and weight gain in Parkinson's disease after subthalamic nucleus stimulation. Neuroendocrinol Lett 2011;32:437-441.
104. Markaki E, Ellul J, Kefalopoulou Z, et al. The role of ghrelin, neuropeptide Y and leptin peptides in weight gain after deep brain stimulation for Parkinson's disease. Stereotact Funct Neurosurg 2012;90:104-112.
105. Andrews ZB, Erion D, Beiler R, et al. Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. J Neurosci 2009;29:14057-14065.
106. Jiang H, Li LJ, Wang J, Xie JX. Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra. Exp Neurol 2008;212:532-537.
107. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000;284:3036-3039.
108. Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16:1347-1356.
109. Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 2006;18:263-283.
110. Nishikawa N, Nagai M, Tsujii T, Iwaki H, Yabe H, Nomoto M. Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. Clin Neuropharmacol 2012;35:182-184.
111. Arts J, Caenepeel P, Verbeke K, Tack J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 2005;54:455-460.
112. Larson JM, Tavakkoli A, Drane WE, Toskes PP, Moshiree B. Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. Neurogastroenterol Motil 2010;16:407-413.
113. Moshiree B, McDonald R, Hou W, Toskes PP. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci 2010;55:675-683.
114. McCallum RW, Cynshi O. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis: a randomized, multicentre, placebo-controlled study. Aliment Pharmacol Ther 2007;26:1121-1130.
115. McCallum RW, Cynshi O. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther 2007;26:107-116.
116. Talley NJ, Verlinden M, Geenen DJ, et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001;49:395-401.
117. Bai Y, Xu MJ, Yang X, et al. A systematic review on intrapyloric botulinum toxin injection for gastroparesis. Digestion 2010;81:27-34.
118. Gil RA, Hwynn N, Fabian T, Joseph S, Fernandez HH. Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients. Parkinsonism Relat Disord 2011;17:285-287.
119. Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003;125:421-428.
120. Lin Z, McElhinney C, Sarosiek I, Forster J, McCallum R. Chronic gastric electrical stimulation for gastroparesis reduces the use of prokinetic and/or antiemetic medications and the need for hospitalizations. Dig Dis Sci 2005;50:1328-1334.